Trial Profile
A study assessing mechanisms of resistance to crizotinib among ROS1-positive lung cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Lung cancer; Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 26 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology